Arcutis Biotherapeutics Cash Flow Statement
NASDAQ: ARQTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
26.58+2.09 (+8.53%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arcutis Biotherapeutics free cash flow
In fiscal 2025, Arcutis Biotherapeutics generated -$5.6 million of operating cash flow and spent $686,000 on capital expenditures. That left free cash flow of -$6.3 million, a free-cash-flow margin of -1.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Arcutis Biotherapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -16.14M | -140.04M | -262.14M | -311.46M | -206.36M | -135.68M | -42.00M | -19.25M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 700.00K | 600.00K | 800.00K | 622.00K | 454.00K | 122.00K | 68.00K | 0 |
| Stock-Based Compensation | 40.36M | 41.73M | 38.81M | 32.68M | 23.89M | 7.94M | 824.00K | 151.00K |
| Change in Working Capital | -34.15M | -14.35M | -22.84M | -9.74M | 3.38M | 14.14M | -1.37M | 2.11M |
| Operating Cash Flow | -5.63M | -112.16M | -247.06M | -257.71M | -174.63M | -113.03M | -42.84M | -14.09M |
| Capital Expenditures | -686.00K | -143.00K | -428.00K | -333.00K | -995.00K | -321.00K | -295.00K | 0 |
| Investing Cash Flow | -30.25M | 28.82M | 180.23M | -87.20M | -75.95M | -181.82M | -26.32M | -11.53M |
| Debt Issued | — | 0 | 0 | 125.00M | 73.99M | 0 | 0 | — |
| Debt Repaid | 0 | -100.00M | 0 | 0 | — | — | — | — |
| Financing Cash Flow | 6.97M | 66.20M | 101.32M | 301.80M | 281.95M | 298.14M | 93.10M | 61.59M |
| Net Change in Cash | -28.74M | -17.37M | 34.45M | -43.12M | 31.37M | 3.29M | 23.94M | 35.98M |
| Free Cash Flow | -6.31M | -112.30M | -247.49M | -258.05M | -175.62M | -113.35M | -43.13M | -14.09M |
This table shows 8 annual periods of Arcutis Biotherapeutics's cash flow statement, from FY 2025 back to FY 2018, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ARQT's reporting calendar. What is a cash flow statement?